admin

If you’ve read my prior articles on Ocugen (NASDAQ:OCGN), you know full well my heavily bearish view about OCGN stock. What’s the story here? The company is trying to bring Covaxin, a Covid-19 vaccine candidate developed by India’s Bharat Biotech, to the U.S. and Canada. Source: shutterstock.com/PhotobyTawat So far, it’s made little progress obtaining Emergency
0 Comments
Big Oil has been out of favor for over a decade. But on the reopen, are the analysts finally bullish? Visit our website: https://www.zacks.com Visit our Stocktwits account: https://stocktwits.com/ZacksResearch Check out our weekly promotion: https://www.zacks.com/promo If you’re interested in our services, please check out Zacks Ultimate: https://www.zacks.com/ultimate/?adid=YOUTUBE&cid=sm-YOUTUBE
0 Comments
If special purpose acquisition companies have jumped the shark, they may have done so with Digital World Acquisition (NASDAQ:DWAC). The so-called Trump special purpose acquisition company (SPAC), Digital World is the blank-check firm that will take the former president’s media firm Trump Media & Technology Group (TMTG) public. Undergirding DWAC stock is the much-eyeballed social
0 Comments
In this article BA ASTR AMZN Rocket 3.1 launches from Kodiak, Alaska. Astra / John Kraus A flurry of space companies filed requests with the Federal Communications Commission on Thursday for new or expanded broadband networks, asking the regulator for approval of nearly 38,000 total satellites. Amazon, Astra, Boeing, Inmarsat, Intelsat, Hughes Network, OneWeb, SpinLaunch,
0 Comments
Despite mixed critical reviews, The Walt Disney Company’s (DIS) latest release Eternals has earned $9.5 million on its opening day in international markets. That figure is the third-highest opening this year after Shang-Chi and the Legend of the Ten Rings and Black Widow, Disney’s previous releases. Eternals, which is part of Disney’s lucrative Marvel Cinematic Universe
0 Comments
CNBC’s Jim Cramer on Friday took comfort in a prediction by Dr. Scott Gottlieb that the pandemic phase of Covid could be over by January. “Dr. Gottlieb basically said the war’s over, and that’s just incredible,” Cramer said. Gottlieb, who had served as FDA chief under former President Donald Trump, is currently a Pfizer board
0 Comments
Income investors are in a difficult position. Interest rates remain near zero, meaning yields across fixed income have declined over the past several years. When it comes to stocks, the rally to all-time highs in the market has caused the average dividend yield of the S&P 500 index to decline to around 1.3%. This is why
0 Comments
Over the trailing year, a majority of my single-company opinions have been at least middle of the road for obvious reasons. Although I do have broader economic concerns, benchmark indices have proven resilient. So, my headline to consider exiting Novavax (NASDAQ:NVAX) stock might seem controversial. Source: Ascannio/Shutterstock.com However, I genuinely believe taking the green ink
0 Comments
Quartr A new start-up is attempting to modernize the investor relations industry to meet the surge of new retail investors. Swedish start-up Quartr recently raised $4.5 million to help build out its product, which includes recordings of earnings calls and financial documents from major companies. Investors in Quartr include executives at the Ritholtz Group —
0 Comments
Corsair (NASDAQ:CRSR) has some two tough headwinds to overcome. First, CRSR stock is a former meme stock carried on a ride by Reddit’s WallStreetBets earlier this year. At the time though, Corsair had strong fundamentals to justify the rally. For much of the year, Corsair has lost momentum. Source: WDphotography / Shutterstock.com Corsair staged one more
0 Comments
It would be fresh in investors memory that Lucid (NASDAQ:LCID) stock surged from below $10 to highs of $64.86. This happened even before the special purpose acquisition company (SPACs) became announced publicly. After the announcement, LCID stock slumped to lows of $20. It’s a perfect example of investors selling on news and I believe that Ocugen
0 Comments